Noema Pharma
Basel, Switzerland · Biotechnology, Health Care, Therapeutics · 32 employees
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms o
Funding history
- Series series b — $147.0M — Dec 2024
Recent signals
- Jan 08, 2025: Noema Pharma Appoints Michael Samar as Chief Financial Officer and Volker Knappertz as Executive Vice President of Research and Development
- Dec 11, 2024: Raised $147.0M in Series series b
- Nov 15, 2023: Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer
See plans & pricing → Track Noema Pharma’s funding, hiring, and signals — with verified contacts — on Fundz.